Healthcare Services

Allogeneic Cell Therapy Market: Future Trends and Outlook

April 17, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Is The Market Size Of The Allogeneic Cell Therapy Market Expected To Scale Between 2026 And 2030?

The allogeneic cell therapy market has experienced substantial growth in its size over recent years. This market is anticipated to expand from $1.2 billion in 2025 to $1.34 billion in 2026, achieving a compound annual growth rate (CAGR) of 11.5%. Historically, this growth was influenced by factors including the initial limited availability of allogeneic cell therapy products, the expansion of early-stage clinical trials, an increasing prevalence of hematological disorders, growing hospital adoption of cell therapies, and a reliance on donor cell banks.

The allogeneic cell therapy market size is projected to experience substantial expansion over the coming years. This market is anticipated to reach $1.97 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.2%. Factors contributing to this growth during the forecast period include progress in stem cell and immune cell engineering, a wider array of dermatological and other therapeutic uses, increased funding for cell therapy manufacturing sites, partnerships forged between hospitals and biotechnology companies, and the integration of automated cell processing techniques. Key trends foreseen for this period encompass a rise in the use of stem cell therapies, greater emphasis on t-cell and NK cell therapies, the broadening of iPSC-based therapeutic uses, an escalating need for personalized cell therapy solutions, and strengthened regulatory supervision along with improved safety protocols.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/allogeneic-cell-therapy-global-market-report

Which Drivers Are Supporting The Allogeneic Cell Therapy Market Growth?

The rising incidence of chronic diseases is anticipated to fuel the expansion of the allogeneic cell therapy market. A chronic disease is an enduring health condition that typically demands continuous medical attention and can restrict daily activities or diminish the quality of life. The widespread occurrence of chronic disease is attributed to altered lifestyle habits, genetic factors, and exposure to chemicals, toxins, and airborne pollutants. Allogeneic cell therapy offers considerable promise for treating a broad spectrum of chronic diseases by employing healthy cells from a donor to repair, replace, or regulate dysfunctional cells or tissues in the recipient. For instance, in January 2023, according to the National Center for Biotechnology Information (NCBI), a US-based medicine library, the number of individuals aged 50 and above who experience one or more chronic illnesses is projected to increase by 99.5% by 2050, growing from 71.52 million in 2020 to 142.66 million. Thus, the escalating prevalence of chronic diseases is a significant driver for the growth of the allogeneic cell therapy market.

What Are The Different Segment Types In The Allogeneic Cell Therapy Market Segment Breakdown?

The allogeneic cell therapy market covered in this report is segmented –

1) By Type: Stem Cell Therapies, Non-Stem Cell Therapies

2) By Therapeutic Area: Hematological Disorders, Dermatological Disorders

3) By End User: Hospitals, Specialty Clinics

Subsegments:

1) By Stem Cell Therapies: Hematopoietic Stem Cell Therapy (Hematopoietic Stem Cells), Mesenchymal Stem Cell Therapy (MSC-Based Therapies), Induced Pluripotent Stem Cells (iPSC-Based Therapies), Neural Stem Cell Therapy

2) By Non-Stem Cell Therapies: T-cell Therapies, Natural Killer (NK) Cell Therapies, Dendritic Cell Therapies

Which Trends Are Expected To Impact The Allogeneic Cell Therapy Market?

Leading firms within the allogeneic cell therapy sector are concentrating on creating novel solutions, including cell processing platforms, to bolster their market standing. These platforms constitute systems and technologies designed for preparing and handling cells in therapeutic contexts, covering their isolation, purification, expansion, modification, and quality control to certify their appropriateness for clinical application. An illustrative example is the collaboration in March 2024 between Getinge, a healthcare company headquartered in Sweden, and CellRev, a UK-based biotechnology firm, which resulted in the introduction of Livit ACE, a platform dedicated to continuous cell processing (Adherent Cell Expansion). This groundbreaking platform integrates cutting-edge automation and bioprocessing technologies, substantially improving the efficiency and scalability of cell manufacturing. Its distinct functionalities comprise advanced cell isolation and purification systems guaranteeing elevated cell purity and viability, strong expansion capacities for generating substantial amounts of therapeutic cells, sophisticated genetic modification instruments for accurate cell engineering, and stringent quality control protocols to assure the safety and effectiveness of the final cell products.

Who Are The Well-Known Companies In The Allogeneic Cell Therapy Market?

Major companies operating in the allogeneic cell therapy market are Novartis AG, Bristol Myers Squibb Company, Takeda Pharmaceutical Company Limited, Bluebird Bio Inc., Poseida Therapeutics Inc., Fate Therapeutics Inc., Fortress Biotech Inc., Sorrento Therapeutics Inc., Eureka Therapeutics Inc., Juno Therapeutics Inc., Adaptimmune Therapeutics plc, Cellectis SA, Ziopharm Oncology Inc., Allogene Therapeutics Inc., Century Therapeutics Inc., Autolus Therapeutics plc, Bellicum Pharmaceuticals Inc., Celyad SA, TILT Biotherapeutics Ltd., CRISPR Therapeutics AG

Get The Full Allogeneic Cell Therapy Market Report:

https://www.thebusinessresearchcompany.com/report/allogeneic-cell-therapy-global-market-report

Which Region Holds The Highest Market Share In The Allogeneic Cell Therapy Market?

North America was the largest region in the allogeneic cell therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the allogeneic cell therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Allogeneic Cell Therapy Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/allogeneic-cell-therapy-global-market-report

Browse Through More Reports Similar to the Global Allogeneic Cell Therapy Market 2026, By The Business Research Company

Autologous Cell Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/autologous-cell-therapy-global-market-report

Cells Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/cells-therapy-global-market-report

Cell Therapy Technologies Market Report 2026

https://www.thebusinessresearchcompany.com/report/cell-therapy-technologies-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795